These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
167 related items for PubMed ID: 35174522
1. Bone-density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy. Park H, Park J, Yoo H, Kim S, Koh JH, Jee JH, Min YK, Chung JH, Kim TH, Kang M, Kim SW. Clin Endocrinol (Oxf); 2022 Jul; 97(1):130-136. PubMed ID: 35174522 [Abstract] [Full Text] [Related]
6. Assessment for bone health in patients with differentiated thyroid carcinoma after postoperative thyroid-stimulating hormone suppression therapy: a new fracture risk assessment algorithm. Jia H, Qu W, Cai X, Li M, Qian Y, Jiang Z, Zhang Z. Front Endocrinol (Lausanne); 2023 Jul; 14():1286947. PubMed ID: 38075039 [Abstract] [Full Text] [Related]
8. Bone-density testing interval and transition to osteoporosis in older women. Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE, Study of Osteoporotic Fractures Research Group. N Engl J Med; 2012 Jan 19; 366(3):225-33. PubMed ID: 22256806 [Abstract] [Full Text] [Related]
10. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. Chen CH, Chen JF, Yang BY, Liu RT, Tung SC, Chien WY, Lu YC, Kuo MC, Hsieh CJ, Wang PW. J Formos Med Assoc; 2004 Jun 19; 103(6):442-7. PubMed ID: 15278189 [Abstract] [Full Text] [Related]
11. Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study. Wang S, Wang Y, Zhu L, He L, Lv M, Zhang H, Wang H, Zhang F, Lai Y, Li Y, Shan Z, Teng W. Endocrine; 2023 Jan 19; 79(1):113-124. PubMed ID: 36089636 [Abstract] [Full Text] [Related]
15. The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma. Moon JH, Jung KY, Kim KM, Choi SH, Lim S, Park YJ, Park DJ, Jang HC. Bone; 2016 Feb 19; 83():104-110. PubMed ID: 26518742 [Abstract] [Full Text] [Related]
17. Bone Mineral Density Screening Interval and Transition to Osteoporosis in Asian Women. Park H, Yang H, Heo J, Jang HW, Chung JH, Kim TH, Min YK, Kim SW. Endocrinol Metab (Seoul); 2022 Jun 19; 37(3):506-512. PubMed ID: 35678100 [Abstract] [Full Text] [Related]
18. High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma. Mazziotti G, Formenti AM, Frara S, Olivetti R, Banfi G, Memo M, Maroldi R, Giubbini R, Giustina A. J Clin Endocrinol Metab; 2018 Mar 01; 103(3):956-964. PubMed ID: 29121201 [Abstract] [Full Text] [Related]
20. Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma. de Melo TG, da Assumpção LV, Santos Ade O, Zantut-Wittmann DE. Thyroid Res; 2015 Mar 01; 8():7. PubMed ID: 26097507 [Abstract] [Full Text] [Related] Page: [Next] [New Search]